Our sister publication DISTRESSED DEAL DATA™ expanded its scope of coverage beginning on January 15th to institute a new category of coverage, titled Upside Alpha Opportunity™. With this coverage, DailyDAC is now making “buy” and “sell” recommendations on select equity securities whose price movements are driven by news of exigent, or even existential circumstances. Our first such recommendation was Lipocine Inc. (ticker: LPCN). LPCN is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, that seeks to improve compliance, absorption, and other objectives with proprietary drug delivery technology.
On January 14th, as we reported on January 15th, LPCN “had received written notice from the staff of the Listing Qualifications Department of the Nasdaq Stock Market indicating Lipocine is no longer in compliance with Nasdaq Listing Rule 5605, which requires a majority independent board, audit committee, and compensation committee.” LPCN closed at $1 that day. It closed at $1.07 on February 11th and yesterday at $1.24. Not bad.
Our newest recommendation concerns Johnson & Johnson (ticker: JNJ) but to know what our recommendation is, you’ll have to subscribe.
|